Deleterious effect of nitric oxide inhibition in chronic hepatopulmonary syndrome
- 1 April 2007
- journal article
- case report
- Published by Ovid Technologies (Wolters Kluwer Health) in European Journal of Gastroenterology & Hepatology
- Vol. 19 (4), 341-346
- https://doi.org/10.1097/meg.0b013e328014a3bf
Abstract
On the basis of limited experimental and clinical studies, increased activity of the vasodilatory nitric oxide–cyclic guanosine monophosphate pathway is considered to play a key role in the pathogenesis of hepatopulmonary syndrome. We report a 46-year-old woman with Child–Pugh class C cirrhosis and progressive dyspnoea for 12 months. Investigations revealed elevated circulating concentrations of nitric oxide metabolites and exhaled nitric oxide levels, an hyperdynamic circulation with low systemic vascular resistance and mean arterial pressure, a large right to left intrapulmonary shunt fraction on radiolabelled macroaggregated albumin perfusion scanning, positive contrast-enhanced echocardiography, reduced diffusion capacity of carbon monoxide, hypoxaemia and orthodeoxyia, all in keeping with severe hepatopulmonary syndrome. Sequential inhibition of the nitric oxide–cyclic guanosine monophosphate pathway using curcumin (diferuloylmethane), terlipressin and methylene blue was associated with substantial improvements in vascular tone and the hyperdynamic circulation. No improvement, however, in the intrapulmonary shunt was demonstrated. Both hypoxaemia and orthodeoxia were substantially, reproducibly and reversibly worsened with all three treatments. Our findings argue against the contention that intrapulmonary shunting and impairment in arterial oxygenation in hepatopulmonary syndrome are necessarily the consequence of on-going, nitric oxide–cyclic guanosine monophosphate-mediated vasodilatation, at least in the chronic stage, and, given the possibility of substantial worsening of pulmonary oxygen exchange, suggest that inhibition of the nitric oxide–cyclic guanosine monophosphate pathway should be avoided in this setting.Keywords
This publication has 21 references indexed in Scilit:
- The Diagnosis and Treatment of Hepatopulmonary SyndromeClinics in Liver Disease, 2006
- Pulmonary-Hepatic vascular Disorders (PHD)European Respiratory Journal, 2004
- Intrapulmonary vascular dilatation and nitric oxide in hypoxemic rats with chronic bile duct ligationJournal of Hepatology, 2003
- Effect on dyspnoea and hypoxaemia of inhaled NG-nitro-L-arginine methyl ester in hepatopulmonary syndromeThe Lancet, 2003
- Curcumin prevents alcohol-induced liver disease in rats by inhibiting the expression of NF-κB-dependent genesAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2003
- Role of Nitric Oxide in Hepatopulmonary Syndrome in Cirrhotic RatsAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Methylene Blue Improves the Hepatopulmonary SyndromeAnnals of Internal Medicine, 2000
- The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndromeGastroenterology, 1997
- Pulmonary vascular dilatation and diffusion-dependent impairment of gas exchange in liver cirrhosisEuropean Respiratory Journal, 1995
- Methylene Blue in the Hepatopulmonary SyndromeNew England Journal of Medicine, 1994